Last reviewed · How we verify
NCT05169177: ROCK-RT
Radio-opaque Contrast Agents for Liver Cancer Targeting With KIM During Radiation Therapy
trial in Liver Neoplasm in 50 participants. Currently enrolling.
31 October 2024
Quick facts
| Lead sponsor | University of Sydney |
|---|---|
| Status | Recruiting now |
| Study type | OBSERVATIONAL |
| Enrollment | 50 |
| Start date | 17 October 2022 |
| Primary completion | 31 October 2024 |
| Estimated completion | 31 October 2026 |
| Sites | 5 locations across Australia |
Conditions studied
- Liver Neoplasm — all drugs for Liver Neoplasm →
Sponsor
University of Sydney
Who can join
18 and older, any sex, with Liver Neoplasm. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This observational study will investigate the properties of image files standardly collected during radiation therapy treatment in a cross-section of liver cancer patients who received stereotactic ablative body radiation therapy (SABR) after trans-catheter arterial chemo emobilisation (TACE). Specifically, it will determine whether the radio-opaque contrast agents in the image files can be detected by tumour-tracking software (KIM).
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Radio-opaque contrast agents for liver cancer targeting with KIM during radiation therapy (ROCK-RT): an observational feasibility study.
Plant N, Mylonas A, Sengupta C, Nguyen DT, et al · · 2024 · PMID 39380004 · DOI 10.1186/s13014-024-02524-4
Verify or expand the search:
- PubMed search for NCT05169177
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Liver Neoplasm
Currently open trials in the same condition.
- NCT07413640 — Variability of Microwave Ablation Volume Based on Clinical, Radiological, Biological, and Tissue Factors · recruiting
- NCT07145801 — Y-90 Treatment Response Using Transarterial Radioembolization · Phase 2 · recruiting
- NCT07335042 — Prediction Model for MINS After Major Hepatobiliary Surgery · recruiting
- NCT07265544 — Single-cell Multiomics and Spatiotemporal Omics Analyze the Mechanism of Liver Degenerative Disease · recruiting
- NCT04864054 — T-Cell Therapy (ECT204) in Adults With Advanced HCC · Phase 1, PHASE2 · recruiting
Other University of Sydney trials
Trials by the same sponsor.
- NCT07173335 — Integrated Healthy Lifestyle and Pain Care for People With Musculoskeletal Conditions Living in Rural Areas. · NA · not yet recruiting
- NCT06908486 — Cognitive Bias Modification for Interpretation (CBM-I) in People With Type 2 Diabetes and Persistent Pain · NA · recruiting
- NCT06159660 — Ventilation Using Radiographic Examination: Functional Lung Imaging Techniques for the Reduction of Toxicity in Function · not yet recruiting
- NCT05568381 — Sleep Disturbance in MCI: A Study of a Cognitive Behavioural Therapy Digital Intervention · NA · completed
- NCT05184790 — LEARN: Learning Environment for Artificial Intelligence in Radiotherapy New Technology · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05169177 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by University of Sydney
- Last refreshed: 30 July 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05169177.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing